Novartis Investigative Site

South Burlington, Vermont 05403

0 studies enrolling now · 9 studies all time

What they study most

Asthma, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Chronic Spontaneous Urticaria, Moderate to Severe Allergic Asthma

Studies at this site

• A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines — Completed
• A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients — Completed
• Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU — Completed
• Dose Finding Study for QAW039 in Asthma — Completed
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. — Completed
• NVA237 BID Versus Placebo Twelve-week Efficacy Study — Completed
• Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma — Completed
• Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks — Completed
• Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma — Completed